Oral extended-release oxymorphone: a new choice for chronic pain relief

Bibliography

• MOULIN DE, CLARK AJ, SPEECHLEY M, MORLEY-FORSTER PK: Chronic pain in Canada--prevalence, treatment, impact and the role of opioid analgesia. Pain Res. Manag. (2002) 7(4):179-184.
   PubMedGoogle Scholar
• ZAGARI MJ, MAZONSON PD, LONGTON WC: Pharmacoeconomics of chronic nonmalignant pain. Pharmacoeconomics (1996) 10(4):356-377.
   PubMed Web of Science ®Google Scholar
• BLYTH FM, MARCH LM, BRNABIC AJ et al.: Chronic pain in Australia: a prevalence study. Pain (2001) 89(2-3):127-134.
   PubMed Web of Science ®Google Scholar
• MILLAR WJ: Chronic pain. Health Rep. (1996) 7(4):47-53.
   PubMedGoogle Scholar
• VERHAAK PF, KERSSENS JJ, DEKKER J, SORBI MJ, BENSING JM: Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain (1998) 77(3):231-239.
   PubMed Web of Science ®Google Scholar
• MCCAFFERY M: Pain management: problems and progress. In: Pain: Clinical Manual. McCaffery M & Pasero C (Eds) Mosby, St. Louis, MO (1999):1-14.
   Google Scholar
• AMERICAN PAIN SOCIETY: Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis. American Pain Society, Chicago, IL, (2002):184.
   Google Scholar
• MERCADANTE S, BRUERA E: Opioid switching: a systematic and critical review. Cancer Treat. Rev. (2006) 32(4):304-315.
   PubMed Web of Science ®Google Scholar
• QUANG-CANTAGREL ND, WALLACE MS, MAGNUSON SK: Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth. Analg. (2000) 90(4):933-937.
   PubMed Web of Science ®Google Scholar
• PAN YX, XU J, MAHURTER L et al.: Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem. Biophys. Res. Commun. (2003) 301(4):1057-1061.
   PubMed Web of Science ®Google Scholar
• PAN L, XU J, YU R et al.: Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience (2005) 133(1):209-220.
   PubMed Web of Science ®Google Scholar
• PASTERNAK GW: Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. (1993) 16(1):1-18.
   PubMed Web of Science ®Google Scholar
• ZHANG J, DING EL, SONG Y: Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA (2006) 296:1619-1632.
   PubMed Web of Science ®Google Scholar
• MCGETTIGAN P, HENRY D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA (2006) 296(13):1633-1644.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION: Cancer pain relief. WHO Office of Publication (1996).
   Google Scholar
• SANDOVAL JA, FURLAN AD, MAILIS-GAGNON A: Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clin. J. Pain (2005) 21(6):503-512.
   PubMed Web of Science ®Google Scholar
• LYNCH ME: A review of the use of methadone for the treatment of chronic noncancer pain. Pain Res. Manag. (2005) 10(3):133-144.
   PubMedGoogle Scholar
• LUGO RA, SATTERFIELD KL, KERN SE: Pharmacokinetics of methadone. J. Pain Palliat. Care Pharmacother. (2005) 19(4):13-24.
   PubMedGoogle Scholar
• SINATRA RS, HYDE NH, HARRISON DM: Oxymorphone revisited. Semin. Anesth. (1988) 7(3):208-215.
   Google Scholar
• PROMMER E: Oxymorphone: a review. Support. Care Cancer (2006) 14(2):109-115.
   PubMed Web of Science ®Google Scholar
• METZGER TG, PATERLINI MG, FERGUSON DM, PORTOGHESE PS: Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus. J. Med. Chem. (2001) 44(6):857-862.
   PubMed Web of Science ®Google Scholar
• CHENG CY, HSIN LW, LIN YP, TAO PL, JONG TT: N-cubylmethyl substituted morphinoids as novel narcotic antagonists. Bioorg. Med. Chem. (1996) 4(1):73-80.
   Google Scholar
• OPANA® ER (oxymorphone hydrochloride). Full Prescribing Information, Endo Pharmaceuticals Inc., Chadds Ford, PA (2006).
   Google Scholar
• LOH HH, LIU HC, CAVALLI A et al.: mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res. Mol. Brain Res. (1998) 54(2):321-326.
   PubMedGoogle Scholar
• MATTHES HW, MALDONADO R, SIMONIN F et al.: Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature (1996) 383(6603):819-823.
   PubMed Web of Science ®Google Scholar
• SCHULLER AG, KING MA, ZHANG J et al.: Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat. Neurosci. (1999) 2(2):151-156.
   PubMed Web of Science ®Google Scholar
• SORA I, LI XF, FUNADA M, KINSEY S, UHL GR: Visceral chemical nociception in mice lacking mu-opioid receptors: effects of morphine, SNC80 and U-50,488. Eur. J. Pharmacol. (1999) 366(2-3):R3-R5.
   Google Scholar
• SORA I, TAKAHASHI N, FUNADA M et al.: Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. U. S. A. (1997) 94(4):1544-1549.
   PubMed Web of Science ®Google Scholar
• ZHU Y, KING MA, SCHULLER AG et al.: Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron (1999) 24(1):243-252.
   PubMed Web of Science ®Google Scholar
• PASTERNAK GW: Molecular biology of opioid analgesia. J. Pain Symptom Manage. (2005) 29(5 suppl.):S2-S9.
   Web of Science ®Google Scholar
• KLEPSTAD P, RAKVAG TT, KAASA S et al.: The 118 A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. (2004) 48(10):1232-1239.
   PubMed Web of Science ®Google Scholar
• LOTSCH J, GEISSLINGER G: Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J. (2006) 6(3):200-210.
   PubMed Web of Science ®Google Scholar
• EDDY NB, LEE LEJ: The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxydihydromorphinone). J. Pharmacol. Exp. Ther. (1959) 125(2):116-121.
   PubMedGoogle Scholar
• ADAMS MP, AHDIEH H: Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy (2004) 24(4):468-476.
   PubMed Web of Science ®Google Scholar
• Kadian® (morphine sulfate sustained release capsules). Full Prescribing Information, Alpharma, Piscataway, NJ (2004).
   Google Scholar
• MS Contin® (morphine sulfate controlled-release tablets). Full Prescribing Information, Purdue Pharma L.P., Stamford, CT (2005).
   Google Scholar
• Avinza® (morphone sulfate extended-release capsules). Full Prescribing Information, Ligand Pharmaceuticals Incorporated, San Diego, CA (2005).
   Google Scholar
• HALE ME, DVERGSTEN C, GIMBEL J: Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J. Pain (2005) 6(1):21-28.
   PubMed Web of Science ®Google Scholar
• GABRAIL NY, DVERGSTEN C, AHDIEH H: Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr. Med. Res. Opin. (2004) 20(6):911-918.
   PubMed Web of Science ®Google Scholar
• HALE ME, AHDIEH H, MA T, RAUCK R: Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J. Pain (2007) 8(2):175-184.
   PubMed Web of Science ®Google Scholar
• SLOAN P, SLATKIN N, AHDIEH H: Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support. Care Cancer (2005) 13(1):57-65.
   PubMed Web of Science ®Google Scholar
• ADAMS MP, AHDIEH H: Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R. D. (2005) 6(2):91-99.
   PubMedGoogle Scholar
• FISKE WD, PHOTIVIHOK G, BENEDEK IH: The effects of graded concentrations of oral ethanol on the in-vivo bioavailability of oxymorphone HCl extended release (ER) tablets. American Society for Clinical Pharmacology and Therapeutics 10th Annual Meeting. Anaheim, CA (21-24 March 2007).
   Google Scholar
• JOHNSON F, WAGNER G, SUN S, STAUFFER J: Effect of alcohol ingestion on the in vivo pharmacokinetics of KADIAN® (morphine sulfate extended-release) capsules. American Academy of Pain Medicine. New Orleans, LA (7-10 February 2007).
   Google Scholar
• CONE EJ, DARWIN WD, BUCHWALD WF, GORODETZKY CW: Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metab. Dispos. (1983) 11(5):446-450.
   PubMed Web of Science ®Google Scholar
• MURTHY BR, POLLACK GM, BROUWER KL: Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J. Clin. Pharmacol. (2002) 42(5):569-576.
   PubMed Web of Science ®Google Scholar
• CHRISTRUP LL: Morphine metabolites. Acta Anaesthesiol. Scand. (1997) 41(1 Pt 2):116-122.
   PubMed Web of Science ®Google Scholar
• ADAMS M, PIENIASZEK HJ, Jr, GAMMAITONI AR, AHDIEH H: Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J. Clin. Pharmacol. (2005) 45(3):337-345.
   PubMed Web of Science ®Google Scholar
• LALOVIC B, PHILLIPS B, RISLER LL, HOWALD W, SHEN DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos. (2004) 32(4):447-454.
   PubMed Web of Science ®Google Scholar
• KIVITZ A, MA C, AHDIEH H, GALER B: A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin. Ther. (2006) 28:352-364.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO AK, BABUL N, AHDIEH H: Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. (2005) 6(5):357-366.
   PubMed Web of Science ®Google Scholar
• MCILWAIN H, AHDIEH H: Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am. J. Ther. (2005) 12(2):106-112.
   PubMedGoogle Scholar
• KATZ J, RAUCK R, AHDIEH H et al.: A 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr. Med. Res. Opin. (2007) 23(1):117-128.
   PubMed Web of Science ®Google Scholar
• AHDIEH H, KERWIN R, YUEN F: Low dose titration with oxymorphone extended release to achieve effective long-term treatment of moderate to severe pain in opioid-naive patients. American Academy of Physician Assistants 34th Annual Physician Assistant Conference. San Francisco, CA (27 May - 1 June 2006).
   Google Scholar
• EISENBERG E, MCNICOL ED, CARR DB: Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA (2005) 293(24):3043-3052.
   PubMed Web of Science ®Google Scholar
• KALSO E, EDWARDS JE, MOORE RA, MCQUAY HJ: Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain (2004) 112(3):372-380.
   PubMed Web of Science ®Google Scholar
• WEBSTER LR, WEBSTER RM: Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. (2005) 6(6):432-442.
   PubMed Web of Science ®Google Scholar
• AKBIK H, BUTLER SF, BUDMAN SH et al.: Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J. Pain Symptom Manage. (2006) 32(3):287-293.
   PubMed Web of Science ®Google Scholar
• BUTLER SF, BUDMAN SH, FERNANDEZ K, JAMISON RN: Validation of a screener and opioid assessment measure for patients with chronic pain. Pain (2004) 112(1-2):65-75.
   PubMed Web of Science ®Google Scholar
• MICHNA E, ROSS EL, HYNES WL et al.: Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J. Pain Symptom Manage. (2004) 28(3):250-258.
   PubMed Web of Science ®Google Scholar
• COAMBS RB, JARRY JL, SANTHIAPILLAI AC, ABRAHAMSOHN RV, ATANCE CM: The SISAP: a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain within general medical practice. Pain Res. Manag. (1996) 1(3):155-162.
   Google Scholar